Vanguard Group
HCWB icon

Vanguard Group’s HCW Biologics HCWB Stock Holding History

Vanguard Group’s Portfolio HCWB Stock Details HCWB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$15K Hold
2,571
– – ﹤0.01% 4314
2025
Q3 		$57.1K Buy
+2,571
New +$67.2K ﹤0.01% 4285
2025
Q2 		– Sell
-1,013
Closed -$68.6K – 4297
2025
Q1 		$68.6K Buy
1,013
+856
+545% +$75.2K ﹤0.01% 4170
2024
Q4 		$16.8K Hold
157
– – ﹤0.01% 4265
2024
Q3 		$20.3K Hold
157
– – ﹤0.01% 4302
2024
Q2 		$24.4K Hold
157
– – ﹤0.01% 4348
2024
Q1 		$65.9K Sell
157
-698
-82% -$223K ﹤0.01% 4284
2023
Q4 		$251K Buy
855
+2
+0.2% +$682 ﹤0.01% 4185
2023
Q3 		$389K Buy
853
+73
+9% +$36.1K ﹤0.01% 4126
2023
Q2 		$406K Buy
780
+22
+3% +$8.75K ﹤0.01% 4176
2023
Q1 		$255K Hold
758
– – ﹤0.01% 4281
2022
Q4 		$348K Buy
758
+361
+91% +$186K ﹤0.01% 4192
2022
Q3 		$218K Buy
397
+35
+10% +$20.1K ﹤0.01% 4403
2022
Q2 		$191K Buy
362
+18
+5% +$10.1K ﹤0.01% 4474
2022
Q1 		$225K Hold
344
– – ﹤0.01% 4519
2021
Q4 		$191K Buy
+344
New +$234K ﹤0.01% 4561

Other funds holding HCWB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JWCA
J.W. Cole Advisors Tampa, Florida $5.83B AUM 32.38% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vanguard Group's HCWB Position: Q4 2025 in Review

Vanguard Group held its HCW Biologics (HCWB) position steady in Q4 2025 at 2,571 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #4314.

Vanguard Group first reported a position in HCWB in Q4 2021 and has held it in 16 quarters since. The position peaked at $406K in Q2 2023. 13 funds tracked by Wall St. Rank hold HCWB as of Q4 2025.

  • Vanguard Group held 2,571 shares of HCW Biologics worth $15K as of Q4 2025.
  • Vanguard Group left its HCW Biologics share count unchanged in Q4 2025.
  • HCW Biologics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4314 holding.
  • Vanguard Group first reported a position in HCW Biologics in Q4 2021 and has held it in 16 quarters since.
  • Vanguard Group's HCW Biologics position peaked at $406K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held HCW Biologics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.